Grace Therapeutics, Inc.
GRCE
$3.02
$0.072.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.60% | -17.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.33% | -2.66% | |||
| Operating Income | 23.33% | 2.66% | |||
| Income Before Tax | -11.11% | -28.23% | |||
| Income Tax Expenses | 28.99% | -17.68% | |||
| Earnings from Continuing Operations | -21.07% | -31.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.07% | -31.14% | |||
| EBIT | 23.33% | 2.66% | |||
| EBITDA | 23.34% | 2.68% | |||
| EPS Basic | -21.05% | -24.55% | |||
| Normalized Basic EPS | -11.13% | -21.77% | |||
| EPS Diluted | -21.05% | -24.29% | |||
| Normalized Diluted EPS | -11.13% | -21.77% | |||
| Average Basic Shares Outstanding | 0.00% | 5.29% | |||
| Average Diluted Shares Outstanding | 0.00% | 5.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||